<DOC>
	<DOCNO>NCT02483208</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics BAY81-8973 Advate intravenous administration .</brief_summary>
	<brief_title>Single Dose Study Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters BAY81-8973 Advate</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Males , age 18 65 year Subjects Severe hemophilia A documented plasma FVIII level &lt; 1 % â‰¥ 150 exposure day FVIII concentrate ( ) support medical record Evidence current past inhibitor antibody History congenital acquire coagulation disorder hemophilia A Platelet count &lt; 75,000/mm3 Abnormal renal function ( serum creatinine &gt; 2 time upper limit normal [ ULN ] range ) Active liver disease verify medical history persistently elevate alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 5 time ULN severe liver disease evidence , limit following : International Normalized Ratio ( INR ) &gt; 1.4 , hypoalbuminemia , portal vein hypertension include presence otherwise unexplained splenomegaly history esophageal varix .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>